CU20180138A7 - Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) - Google Patents

Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Info

Publication number
CU20180138A7
CU20180138A7 CU2018000138A CU20180138A CU20180138A7 CU 20180138 A7 CU20180138 A7 CU 20180138A7 CU 2018000138 A CU2018000138 A CU 2018000138A CU 20180138 A CU20180138 A CU 20180138A CU 20180138 A7 CU20180138 A7 CU 20180138A7
Authority
CU
Cuba
Prior art keywords
mri
nanoparticles
magnetic resonance
contrast agents
detection
Prior art date
Application number
CU2018000138A
Other languages
English (en)
Other versions
CU24583B1 (es
Inventor
Martínez Alberto Bencomo
García Alicia Marcelina Díaz
Dalmau Evelio González
Rodríguez Andy Guzmán
Rodríguez Armando José Hernández
Mesa Claudia Iriarte
Chaviano Samila León
Quevedo Armando Augusto Paneque
Molina Israel Reyes
Marrero Suchitil Rivera
Izquierdo Julio Ricardo Rodríguez
Chryslaine Rodríguez-Tanty
Carrazana Marquiza Sablón
Menéndez Del Valle Roberto Soto
Original Assignee
Centro De Neurociencias De Cuba Biocubafarma
Facultad De Quimica Univ De La Habana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Neurociencias De Cuba Biocubafarma, Facultad De Quimica Univ De La Habana filed Critical Centro De Neurociencias De Cuba Biocubafarma
Priority to CU2018000138A priority Critical patent/CU24583B1/es
Priority to CA3118959A priority patent/CA3118959A1/en
Priority to EP19750050.7A priority patent/EP3878475A1/en
Priority to JP2021525088A priority patent/JP7418429B2/ja
Priority to PCT/CU2019/050005 priority patent/WO2020094161A1/es
Priority to KR1020217017311A priority patent/KR102931218B1/ko
Priority to CN201980083238.6A priority patent/CN113226381B/zh
Priority to US17/291,996 priority patent/US12311036B2/en
Priority to MX2021005232A priority patent/MX2021005232A/es
Priority to BR112021008773-7A priority patent/BR112021008773A2/pt
Publication of CU20180138A7 publication Critical patent/CU20180138A7/es
Priority to ZA2021/03859A priority patent/ZA202103859B/en
Publication of CU24583B1 publication Critical patent/CU24583B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

<p>Esta invención se relaciona con las ramas de Ia Química y Ia Física aplicadas a Ia medicina y se refiere a la obtención de nanopartículas de óxidos metálicos de fórmula general I,</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>cuyos sustituyentes R1, R2 y R3 están expuestos en la descripción y reivindicaciones. Estas nanopartículas magnéticas, recubiertas, funcionalizadas y conjugadas a compuestos naftalénicos afines a los aglomerados y placas ß-amiloides presentes en las enfermedades neurodegenerativas, atraviesan la barrera hematoencefálica (BHE) sin el empleo de ningún agente disruptor de membrana. Estos compuestos se utilizan en la detección temprana y no invasiva de aglomerados y placas amiloideas mediante la técnica de imagen por Resonancia Magnética (IRM) y son capaces de actuar como agentes de contraste para IRM en el diagnóstico temprano y no invasivo de la enfermedad de Alzheimer (EA).</p>
CU2018000138A 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) CU24583B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)
KR1020217017311A KR102931218B1 (ko) 2018-11-06 2019-05-13 자기 공명 영상(MRI)에 의한 β-아밀로이드 플라크의 검출용 조영제로서 나프탈렌 유도체와 접합된 금속 산화물 나노입자
EP19750050.7A EP3878475A1 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images
JP2021525088A JP7418429B2 (ja) 2018-11-06 2019-05-13 磁気共鳴画像法（ＭＲＩ）によるβ－アミロイドプラークの検出のための造影剤としてのナフタレン誘導体と結合した金属酸化物ナノ粒子
PCT/CU2019/050005 WO2020094161A1 (es) 2018-11-06 2019-05-13 Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética
CA3118959A CA3118959A1 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of .beta.-amyloid plaques by magnetic renosance images (mri)
CN201980083238.6A CN113226381B (zh) 2018-11-06 2019-05-13 作为用于通过磁共振成像检测β-淀粉样斑的造影剂的与萘衍生物缀合的金属氧化物纳米粒
US17/291,996 US12311036B2 (en) 2018-11-06 2019-05-13 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images
MX2021005232A MX2021005232A (es) 2018-11-06 2019-05-13 Nanoparticulas de oxidos metalicos conjugados con derivados de naftaleno como agentes de contrastes para la deteccion de placas amiloides por resonancia magnetica (mri).
BR112021008773-7A BR112021008773A2 (pt) 2018-11-06 2019-05-13 Nanoparatículas de óxidos metálicos conjugadas com derivados de naftaleno como agentes de contraste para a detecção de placas beta amiloides por imagens de ressonância magnética
ZA2021/03859A ZA202103859B (en) 2018-11-06 2021-06-04 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Publications (2)

Publication Number Publication Date
CU20180138A7 true CU20180138A7 (es) 2020-10-20
CU24583B1 CU24583B1 (es) 2022-02-04

Family

ID=67551036

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000138A CU24583B1 (es) 2018-11-06 2018-11-06 Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Country Status (11)

Country Link
US (1) US12311036B2 (es)
EP (1) EP3878475A1 (es)
JP (1) JP7418429B2 (es)
KR (1) KR102931218B1 (es)
CN (1) CN113226381B (es)
BR (1) BR112021008773A2 (es)
CA (1) CA3118959A1 (es)
CU (1) CU24583B1 (es)
MX (1) MX2021005232A (es)
WO (1) WO2020094161A1 (es)
ZA (1) ZA202103859B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24720B1 (es) * 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CN114306650B (zh) * 2022-01-21 2022-12-06 南方医科大学 一种磁性四氧化三铁纳米粒及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314794A1 (en) * 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US20110171715A1 (en) * 2008-04-22 2011-07-14 Industrial Technology Research Institute Biocompatible polymer and magnetic nanoparticle with biocompatibility
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
CU24012B1 (es) 2010-10-19 2014-06-27 Ct De Neurociencias De Cuba Nuevos derivados de naftaleno y sus procedimientos de obtención para el diagnóstico in vivo de la enfermedad de alzheimer a través de técnicas de imágenes
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
TW201838658A (zh) * 2017-04-17 2018-11-01 香港中文大學 用於藉由磁振造影(mri)早期診斷阿兹海默症之奈米顆粒造影劑

Also Published As

Publication number Publication date
MX2021005232A (es) 2021-08-11
US12311036B2 (en) 2025-05-27
ZA202103859B (en) 2022-07-27
CA3118959A1 (en) 2020-05-14
EP3878475A1 (en) 2021-09-15
CU24583B1 (es) 2022-02-04
BR112021008773A2 (pt) 2021-10-26
CN113226381A (zh) 2021-08-06
WO2020094161A1 (es) 2020-05-14
JP2022515706A (ja) 2022-02-22
KR20210091216A (ko) 2021-07-21
US20210290782A1 (en) 2021-09-23
KR102931218B1 (ko) 2026-02-25
CN113226381B (zh) 2023-09-19
JP7418429B2 (ja) 2024-01-19

Similar Documents

Publication Publication Date Title
Bort et al. Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI
Kandasamy et al. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics
Cohen et al. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta
Zhang et al. Engineering lanthanide-based materials for nanomedicine
Tang et al. Macromolecular MRI contrast agents: structures, properties and applications
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
CY1124113T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς
ECSP23070062A (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
ES2620177T3 (es) Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP6722663B2 (ja) マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
Lim et al. A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis (thiosemicarbazonato) copper (ii) complex that binds to amyloid-β plaques
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CU20180138A7 (es) Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CR20180307A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY35147A (es) Anticuerpos anti-ceacam5 y usos de éstos.
AR104307A1 (es) Tetralinas de ácido 3-espirocíclico-6-hidroxámico como inhibidores de hdac
WO2014160871A8 (en) Methods and agents for treating alzheimer&#39;s disease
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
JP2017503798A5 (es)
EP2808036A4 (en) SUPERPARAMAGNETIC NANOPARTICLES AS CONTRACTS FOR MAGNETIC RESONANCE TOMOGRAPHY (MRI) OF A MAGNETIC SENSITIVITY (T2 *)
BR112013025633A2 (pt) nanopartículas à base de lipídios
JP2018145180A5 (es)
US9186423B1 (en) Compound of radiocontrast agent for tau protein